Toggle light / dark theme

Optogenetics has revolutionized neuroscience understanding by allowing spatiotemporal control over cell-type specific neurons in neural circuits. However, the sluggish development of noninvasive photon delivery in the brain has limited the clinical application of optogenetics. Focused ultrasound (FUS)-derived mechanoluminescence has emerged as a promising tool for in situ photon emission, but there is not yet a biocompatible liquid-phase mechanoluminescence system for spatiotemporal optogenetics. To achieve noninvasive optogenetics with a high temporal resolution and desirable biocompatibility, we have developed liposome (Lipo@IR780/L012) nanoparticles for FUS-triggered mechanoluminescence in brain photon delivery. Synchronized and stable blue light emission was generated in solution under FUS irradiation due to the cascade reactions in liposomes.

Humans and other animals with brains perhaps aren’t the only beings on the planet to experience consciousness, says a study in the journal EMBO Reports.

Consciousness instead underpins all life forms, from the smallest cells to the most complex organisms. Far from being limited to creatures like ourselves, the cell-based of consciousness frames the phenomenon a fundamental part of life itself.

Conventional thinking about consciousness—called the standard model of consciousness—focuses on the brain, supposing only complex organisms like humans and animals have it. But the new cell-based theory argues that consciousness started with the very first cells that emerged about 3.8 billion years ago and plants, bacteria and even amoebas have it.

A “chaperone” molecule that slows the formation of certain proteins reversed disease signs, including memory impairment, in a mouse model of Alzheimer’s disease, according to a study from researchers at the Perelman School of Medicine at the University of Pennsylvania.

In the study, published in Aging Biology, researchers examined the effects of a compound called 4-phenylbutyrate (PBA), a fatty-acid molecule known to work as a “chemical chaperone” that inhibits . In mice that model Alzheimer’s disease, injections of PBA helped to restore signs of normal proteostasis (the protein regulation process) in the animals’ brains while also dramatically improving their performance on a standard memory test, even when administered late in the disease course.

“By generally improving neuronal and cellular health, we can mitigate or delay ,” said study senior author Nirinjini Naidoo, Ph.D., a research associate professor of Sleep Medicine. “In addition, reducing proteotoxicity— to the cell that is caused by an accumulation of impaired and misfolded proteins—can help improve some previously lost brain functions.”

Neurons communicate through chemical signals known as neurotransmitters. Researchers at St. Jude Children’s Research Hospital, leveraging their expertise in structural biology, have successfully elucidated the structures of the vesicular monoamine transporter 2 (VMAT2), a key component of neuronal communication.

By visualizing VMAT2 in different states, scientists now better understand how it functions and how the different shapes the protein takes influence drug binding — critical information for drug development to treat hyperkinetic (excess movement) disorders such as Tourette syndrome. The work was recently published in the journal Nature.

Precise observation using ultra-high magnetic field 7T MRI.

For the first time, a research team in Korea has discovered there is a significant relationship between depression and the taurine concentration in the hippocampus, an area of the brain responsible for memory and learning functions. This discovery provides the opportunity to publicize the role and importance of taurine in future prevention, diagnosis, and treatment of depression.

Advanced imaging techniques reveal key insights.

“I believe we have found one of the brain’s prototypes for building sequences” says Professor Edvard Moser.


Scientists at NTNU’s Kavli Institute for Systems Neuroscience in Norway have discovered a pattern of activity in the brain that serves as a template for building sequential experiences.

“I believe we have found one of the brain’s prototypes for building sequences,” says Professor Edvard Moser. He describes the activity pattern as “a fundamental algorithm that is intrinsic to the brain and independent of experience.”

A supercomputer scheduled to go online in April 2024 will rival the estimated rate of operations in the human brain, according to researchers in Australia. The machine, called DeepSouth, is capable of performing 228 trillion operations per second.

It’s the world’s first supercomputer capable of simulating networks of neurons and synapses (key biological structures that make up our nervous system) at the scale of the human brain.

DeepSouth belongs to an approach known as neuromorphic computing, which aims to mimic the biological processes of the human brain. It will be run from the International Center for Neuromorphic Systems at Western Sydney University.